Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
10:10am, Thursday, 31'st Jul 2025
Sanofi SA SNY reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.
Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact
08:33am, Thursday, 31'st Jul 2025
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.
Sanofi revises annual sales growth expectations on strong Dupixent demand
01:41am, Thursday, 31'st Jul 2025
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer tr
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
01:00am, Wednesday, 30'th Jul 2025
Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
01:42pm, Monday, 28'th Jul 2025
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
10:00am, Sunday, 27'th Jul 2025
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Da
Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
01:00am, Friday, 25'th Jul 2025
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
10:00am, Tuesday, 22'nd Jul 2025
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Dan
France's Sanofi to acquire biotech firm Vicebio for $1.15 bln
01:43am, Tuesday, 22'nd Jul 2025
French pharmaceuticals company Sanofi said on Tuesday it agreed to acquire British private biotechnology firm Vicebio for a total of $1.15 billion, in a bid to expand its respiratory vaccines portfoli
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
01:30am, Tuesday, 22'nd Jul 2025
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately hel
Press Release: Sanofi completes acquisition of Blueprint Medicines
01:00am, Friday, 18'th Jul 2025
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfol
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
10:00am, Thursday, 17'th Jul 2025
NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Dan
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
12:56pm, Wednesday, 16'th Jul 2025
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
Thermo Fisher acquires Sanofi's New Jersey manufacturing site
09:35am, Wednesday, 16'th Jul 2025
Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical medicines for the French drugmaker.
Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing
08:00am, Wednesday, 16'th Jul 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additi
